Deals
Lilly Bought Engage Bio's DNA Platform for $202M
Eli Lilly paid up to $202M for a preclinical biotech with zero disclosed programs: the platform bet driving its $21B 2026 buying spree.
M&A & Fundraising Desk
Deals, rounds, IPOs, and busts.
M&A, financings, public offerings, insolvencies. Who paid what, why the milestone structure matters, and which regulator picks up the phone next.
6
Stories this week
2
Reporters
10
Active topics
All filings
102 filings
No filings match this filter in the first page.
About this desk
What we cover
M&A in biotech and pharma — from $50M asset swaps to $50B megadeals. Fundraising rounds where the Series letter and syndicate composition matter. IPOs that set benchmarks or signal a window closing. Bankruptcies and restructurings that shift pipeline assets into new hands. We track who bought what, for how much, and what the milestone structure says about risk allocation.
Why the compliance angle
Deal activity is a leading indicator for where regulatory scrutiny goes next. An acquirer inheriting FDA commitments, an IPO-bound company adjusting disclosures, a VC-backed buyout that triggers antitrust review — the compliance story usually follows the money. A $1B+ biotech acquisition changes the agency conversation; a failed IPO forces shareholder communications that invite SEC review.
Frequently asked
What qualifies as a "deal" for The 483? +
M&A transactions, equity financings (Series A onwards), IPOs, and insolvency events where at least one party is a US- or EU-registered entity in biopharma, medtech, or fintech. We don't cover corporate reshuffles without external capital.
Do you cover private market rounds? +
Yes — Series A through late-stage rounds with named syndicates. Seed rounds only when the investors or the amount make it notable.
How fast do you publish after an announcement? +
Usually within 2–6 hours of the initial SEC filing or company press release. Deals above $1B get priority.
Do you publish deal rumors? +
No. We require at least one primary source — company press release, SEC filing, or a confirmed outlet — before publishing.